Essential CRO and Ecron Acunova Form Global Alliance
Gurnee, IL, August 3, 2009
Essential CRO and Ecron Acunova have announced the formation of a global strategic alliance. The alliance network is established through a combination of Essential CRO’s presence in Gurnee, Illinois with Ecron Acunova, based in Bangalore, India with its U.S. office in Princeton, NJ and an established presence, headquartered in Frankfurt, Germany, across 14 countries in Europe.
While Essential and Ecron Acunova have been partners for several years, the magnitude of project size and positive feedback from sposors on the combined team execution have influenced the establishment of this alliance. The alliance has passed several international clients QA audits over the past two years reinforcing the quality of execution. In the past six months the alliance has won global projects in the eight figure range in over 14 countries from leading mid-sized biotech and large pharma sponsors.
About Essential
Essential provides CRO and patient recruitment services. The organization’s two main service offerings of CRO and patient recruitment services are independent, yet fully integrated. Visit www.essentialgroupinc.com for more information.
About Ecron Acunova
Ecron Acunova is headquartered in Bangalore, India with European HQ in Frankfurt, Germany and US HQ in Princeton, NJ. Ecron Acunova provides services for Phase I–IV clinical research, including Clinical Trial Management, Clinical Data Management, PK/PD services and Central Lab with its research centers in Germany and India. Ecron Acunova provides clinical development services to the pharmaceutical, biotechnology, nutritional, device and medical diagnostics industries. Visit www.ecronacunova.com for more information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
